GlassScriptPhysician profile
Michael A Hater
NPI 1982643904
$4,985.63
in general payments reported to CMS, 2019-2025
24 companies · $600 in 2025
The $600 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $546 · 2020: $502 · 2021: $913 · 2022: $721 · 2023: $1,064 · 2024: $639 · 2025: $600.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,303.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,303.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $1,043.35 | 2019-2025 | Cequa |
| Bausch & Lomb Americas INC. | $723.75 | 2022-2025 | Vyzulta, Miebo, Xiidra |
| Oyster Point Pharma, INC. | $525.09 | 2022-2025 | Tyrvaya, Ryzumvi |
| Novartis Pharmaceuticals Corporation | $436.80 | 2021-2023 | |
| Dompe US, INC. | $277.85 | 2020-2025 | Oxervate |
| Alcon Vision LLC | $259.32 | 2019-2025 | Tryptyr, Unity, Eysuvis |
| Kala Pharmaceuticals, INC. | $247.56 | 2019-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $205.42 | 2019-2021 | |
| Amgen INC. | $201.43 | 2025 | Tepezza |
| Allergan, INC. | $165.18 | 2019-2021 | |
| Glaukos Corporation | $112.59 | 2019-2023 | |
| Tarsus Pharmaceuticals, INC. | $112.53 | 2024-2025 | Xdemvy |
| Genentech USA, INC. | $105.30 | 2021 | |
| Lombart Brothers, INC. | $86.43 | 2019 | |
| Harrow Eye, LLC | $84.37 | 2023-2025 | Vevye, Iheezo |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $64.93 | 2024 | Tecnis Iol |
| Mallinckrodt Enterprises LLC | $64.49 | 2019 | |
| Biotissue Holdings INC. | $56.11 | 2019-2025 | |
| Aerie Pharmaceuticals, INC. | $53.31 | 2020 | |
| Eyepoint US, INC. | $43.78 | 2021 | |
| Eyevance Pharmaceuticals LLC | $42.81 | 2022-2023 | Flarex |
| Horizon Therapeutics Plc | $36.18 | 2023 | Tepezza |
| Ivantis, INC | $21.93 | 2021 | |
| Dutch Ophthalmic, USA | $15.12 | 2024 | Tissueblue, Eva, Combined Machine |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Hater listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.